Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

This study has been completed.

Sponsor:

Information provided by:

NIH AIDS Clinical Trials Information Service

ClinicalTrials.gov Identifier:

NCT00002031

First received: November 2, 1999

Last updated: June 23, 2005

Last verified: February 1990

History of Changes

Purpose

To evaluate the effect of application of Dinitrochlorobenzene (DNCB) on the number, morphology, and antigen expression of epidermal Langerhans cells in AIDS and AIDS related complex (ARC) patients.

Condition	Intervention
HIV Infections	Drug: Dinitrochlorobenzene

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

Resource links provided by NLM:

Genetics Home Reference related topics: complement factor I deficiency

MedlinePlus related topics: HIV/AIDS

U.S. FDA Resources

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Patients must have the following:

Stage III or IV HIV infection.
Provide informed consent.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

Kaposi's sarcoma lesions in the proposed treatment sites.
Liable to require radiation or chemotherapy during the course of the study.
Not likely to survive the length of the study.
Obvious ultra-violet-irradiated skin damage in the treatment areas and anyone with recent UV exposure or likely to have such exposure (e.g.:
holiday tans obtained in Hawaii, members of UV box tanning salons, etc.) Allergy to lidocaine.

Concurrent Medication:

Excluded:

Other Immunomodulators.

Concurrent Treatment:

Excluded:

Radiation.

Patients with the following are excluded:

Kaposi's sarcoma lesions in the proposed treatment sites.
Liable to require radiation or chemotherapy during the course of the study.
Not likely to survive the length of the study.
Obvious ultra-violet-irradiated skin damage in the treatment areas.
Allergy to lidocaine.

Prior Medication:

Excluded:

Prior DNCB therapy.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002031

Locations

United States, California
San Francisco AIDS Clinic / San Francisco Gen Hosp
San Francisco, California, United States, 941102859

Sponsors and Collaborators

University of California, San Francisco

More Information

Publications:

Stricker RB, Elswood BF. Dendritic cells and dinitrochlorobenzene (DNCB): a new treatment approach to AIDS. Immunol Lett. 1991 Aug;29(3):191-6. Review. Erratum in: Immunol Lett 1992 Aug;33(3):316.

ClinicalTrials.gov Identifier:	NCT00002031 History of Changes
Other Study ID Numbers:	047A
Study First Received:	November 2, 1999
Last Updated:	June 23, 2005
Health Authority:	United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:

Langerhans Cells
Dinitrochlorobenzene
Acquired Immunodeficiency Syndrome
AIDS-Related Complex

Additional relevant MeSH terms:

HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases

Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases

ClinicalTrials.gov processed this record on June 18, 2013

To Top